Lethal Perinatal Thrombosis in Mice Resulting From the Interaction of Tissue Factor Pathway Inhibitor Deficiency and Factor V Leiden
- 7 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (18) , 2139-2142
- https://doi.org/10.1161/01.cir.0000017361.39256.82
Abstract
Background — Factor V Leiden (FVL) is a common genetic risk factor for thrombosis in humans. The incomplete penetrance of FVL suggests important contributions from other genetic or environmental modifying factors. Variation in the expression of tissue factor pathway inhibitor ( TFPI ) has also been proposed as a risk factor for venous thrombosis and has been shown to enhance the prothrombotic effect of FVL in vitro. Methods and Results — To examine the potential in vivo interaction between Tfpi and FvL , we analyzed crosses between mice carrying FvL and a deficiency of TFPI. The Fv Q/Q , Tfpi +/− genotype was nearly completely fatal in the early perinatal period. Increased fibrin deposition was observed in multiple organs from the Fv Q/Q , Tfpi +/− fetuses, suggesting disseminated thrombosis. Conclusions — These observations demonstrate the prothrombotic effect of modest variations in the level of TFPI expression and suggest that TFPI could be an important genetic modifier for the thrombosis associated with FVL in humans.Keywords
This publication has 15 references indexed in Scilit:
- Genetic risk factors of venous thrombosisHuman Genetics, 2001
- Prothrombotic phenotype of protein Z deficiencyProceedings of the National Academy of Sciences, 2000
- The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin MutationNew England Journal of Medicine, 1999
- Total and free levels of tissue factor pathway inhibitorBlood Coagulation & Fibrinolysis, 1999
- Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDENPublished by Elsevier ,1997
- World distribution of factor V LeidenThe Lancet, 1995
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995
- Resistance to Activated Protein C as a Basis for Venous ThrombosisNew England Journal of Medicine, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitorNature, 1989